Mizuho Securities analyst Salim Syed maintained a Buy rating on Gilead Sciences (GILD) today and set a price target of $81.00. The company’s shares closed last Friday at $82.69, close to its 52-week high of $85.98.
According to TipRanks.com, Syed has 0 stars on 0-5 star ranking scale with an average return of -10.3% and a 42.0% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Coherus Biosciences.
Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $76.44, a -10.3% downside from current levels. In a report issued on April 3, Oppenheimer also maintained a Buy rating on the stock with a $80.00 price target.
See today’s analyst top recommended stocks >>
Based on Gilead Sciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.88 billion and net profit of $2.7 billion. In comparison, last year the company earned revenue of $5.8 billion and had a net profit of $3 million.
Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GILD in relation to earlier this year. Most recently, in February 2020, Kevin Lofton, a Director at GILD bought 21,720 shares for a total of $426,364.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firms primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster, CA.
Read More on GILD:
